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ABSTRACT
Introduction. Traditionally, digestive and 
ophthalmic symptoms have been described 
as predominant in the clinical presentation 
of active infection with cytomegalovirus 
(AICMV). Nevertheless, it seems that this 
has changed following the introduction of 
antiretroviral therapy (ART). Nowadays, 
respiratory infection (RI) in HIV-infected 
patients is the first reason for consulting 
an Emergency Department (ED). Among 
these patients, the mortality is important.
Aim. To determine if RI in HIV-infected 
patients is a common manifestation of AI-
CMV and to describe the changes in clini-
cal presentation of AICMV in relation to 
what was previously described.
Methods. A single-center, retrospective 
study was conducted over the duration of 
nine years (2005-2015). All HIV patients 
who consulted our emergency depart-
ment with respiratory symptoms and were 
diagnosed with AICMV were included. 
Isolation of other co-infecting microor-
ganisms and mortality in the series are also 
described.
Results. 56 HIV-infected patients with AI-
CMV were identified. RI was diagnosed 
in 34 (61%), 31(91%) patients had pneu-
monia and 3(9%) pulmonary tuberculosis. 
The most frequently isolated microorgan-
ism was P. jirovecii, in 21 (68%) patients. 
Bacteria were isolated in five patients 
(15%). Five patients died from RI (9%). 
No patient had acute retinitis or any other 
ophthalmic involvement.
Conclusion. Clinical manifestation of AI-
CMV in HIV patients has changed, and RI 
is the most common manifestation, caused 
by opportunistic microorganisms with 9% 
mortality.
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INTRODUCTION
Human cytomegalovirus (CMV) infection 
is highly prevalent in the world, especially 
in developing countries where 90% of the 
population is infected with this virus, while 
infection is estimated at 60% in developed 
countries. (1) In immunocompetent in-
dividuals, the infection is usually asymp-
tomatic, mild or causes a mononucleosis 
syndrome but in immunosuppressed pa-
tients it behaves as an opportunistic patho-
gen, causing severe damage. (2)
Specifically in HIV-infected patients with 
severe immune suppression, it manifests 
in up to 40% of them throughout their life, 
usually as ophthalmic manifestations or 
digestive. (3) However, following the in-
troduction of combination antiretroviral 
therapy (cART), prognosis has improved, 
and consequently active infection with cy-
tomegalovirus (AICMV) has decreased. 
(4)
Respiratory infection (RI) is one of several 
indicators of AICMV, and the main cause 
for attending an Emergency Department 
(ED) in HIV-infected patients. Commu-
nity-acquired pneumonia is the leading 
cause of death in these patients. (5) Al-
though the incidence of RI has decreased, 
and its etiology has changed due to the in-
troduction of cART, it has a non-negligible 
mortality and often requires admission to 
an intensive care unit (ICU). (6)
The study objectives were to clarify, in a co-
hort of HIV-infected patients, if the usual 
clinical manifestations of AICMV have 
changed, and if RI has an important role in 
the presentation of AICMA, Furthermore, 
we wanted to find out which microorgan-
isms cause it, and what the 30-day mortal-
ity is.
METHODS
Design, setting, and population
This is a single-center retrospective study 
taking place during the course of nine years 
(2006-2015) and performed at our hospi-
tal which conducts annual monitoring of 
5000 HIV-infected patients. All patients 
with HIV infection who attended our ED 
with respiratory symptoms and were diag-
nosed with AICMV were included.
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Study protocol
AICMV was defined as the isolation of 
the virus or evidence of CMV replication, 
regardless of symptoms, by polymerase 
chain reaction (PCR); culture in any fluid 
or body tissue; and CMV disease, where 
the infected patient, besides virus replica-
tion, shows symptoms or signs of disease 
(viral syndrome or visceral involvement). 
(7,8) For the diagnosis of pneumonia, re-
gardless of etiology, the criteria of the In-
fectious Diseases Society of America were 
applied. (9) Severe immunosuppression 
was defined as the presence of a CD4 count 
of less than 200 cells/µl in blood.
Measurements
The following epidemiological, clinical and 
laboratory variables were collected from 
patients: sex, age, previous opportunistic 
infections, associated comorbidities, route 
of HIV transmission, toxic habits, cART, 
number of CD4, CD8 lymphocytes and 
HIV viral load (VL) (prior to admission), 
coinfection with hepatitis C virus (HCV), 
target organ of CMV infection, presence 
of fever, need for mechanical ventilation 
(MV), number of total leukocytes, plate-
lets, hemoglobin, liver profile, ICU admis-
sion, and 30-day mortality.
To determine the presence of pathogens, 
the results of blood cultures (Bactec 9240; 
Becton Dickinson), Gram stain and culture 
of respiratory samples, Ziehl-Neelsen stain 
and culture of mycobacteria, silver stain to 
detect P. jirovecii, and PCR to identify the 
presence of other respiratory viruses, were 
collected. For the diagnosis of CMV, viral 
culture of bronchoalveolar lavage (BAL) 
and CMV detection by real-time quantita-
tive PCR (Q-CMV Real Time, Nanogen) 
in plasma, BAL and / or biopsy of the af-
fected organ, were performed.
Statistical analysis
Categorical variables were expressed as 
frequencies and percentages, and continu-
ous variables were expressed as mean and 
standard deviation. Results were consid-
ered statistically significant if the p-value 
was less than 0.05. To evaluate the relation-
ship between quantitative variables, T-test 
for independent samples was used in nor-
mally distributed variables and U-Mann 
Whitney in those not normally distributed. 
The chi-squared was used to evaluate the 
relationship between qualitative variables. 
All statistical analyses were calculated us-
ing SPSS version 20.0 (Chicago, IL, USA).
RESULTS
56 HIV-infected patients were identified 
with AICMV. The mean age was 43 years, 
44 (79%) were male, and 6 (11%) had 
HCV coinfection. HIV transmission was 
through sexual contact for 48 (88%) pa-
tients and IDUs (drug abuse) for 8 (22%). 
Only 15 (27%) were receiving cART. The 
median CD4 count was 31 cells/µl (IRQ 
= 61), HIV VL 284050 copies / ml (IRQ 
= 631,625), the average blood CMV VL 
was 68569.94 ± 26718,5 copies / ml, and in 
BAL, 3359.0 ± 47985,93 copies / ml. Nine-
teen (34%) patients were admitted to ICU. 
The most common clinical sign was fever 
(59%). The other variables are shown in 
table 1.
Out of the 56 patients who had AICMV, 
34 (61%) of them presented with RI, as a 
clinical manifestation, to the ED. The low-
er airways were always affected of which 
31 (92%) patients had pneumonia and 3 
(8%) had pulmonary tuberculosis (TB). 
In 29 (85%) patients, CMV coinfection 
was detected with other microorganisms: 
Mycobacterium tuberculosis in 3 (8%), P. 
jirovecii in 21 (68%), Haemophilus influ-
enzae in 2 (6%), Klebsiella pneumoniae 
in 1 (3%), Pseudomonas aerouginosa in 
1 (3%), Streptococcus pneumoniae in 1 
(3%). In five (16%) patients, CMV was the 
only pathogen isolated.(table 1). All pa-
tients diagnosed with pneumonia caused 
by P. jirovecii or TBC showed a degree of 
severe immunosuppression. In our se-
ries, no patient had acute retinitis or any 
other ophthalmic involvement and only 
8 patients (14%) presented with digestive 
symptoms. Others clinical manifestations 
are shown in table 2.
The overall 30-day mortality was 18% (10 
patients) and 5 (50%) of them had a respir-
atory infection, 2 (12%) had an infection 
of the central nervous system (cerebral 
toxoplasmosis), 1 (6%) died from liver 
failure (HCV coinfected patient), 1 (6%) 
from hematologic disease (lymphoma) 
and 1 (6%) from intestinal infection (lam-
blia giardiasias). Death from respiratory 
infection, compared to the total sample, 
occurred in five patients (9%): in 3 (60%) 
cases due to pneumonia by P. jirovecii, in 1 
(20%) by H. influenzae and in 1 (20%) by 
S. pneumoniae. The only variables associ-
ated with mortality were: the need for ICU 
admission (X2 = 17.7; p <0.001) and the 
need for MV (X2 = 28.3; p <0.001) (table 
3). The mortality rate for patients admitted 
to the ICU was 47%.
The CMV viral load in the blood showed 
no discriminative power for mortality 
(30846.7±69235.8 vs. 2100034.8±573143.6; 
U=84; p=0.197), while the viral load 
in BAL was significantly higher in pa-
tients who died (103648.0±40658.7 vs 
9929.3±16066.3; U=12; p=0.208).
Table1. Descriptive analysis of the HIV and active infection by cytomegalovirus (AICMV) population.
Age (mean) 43
Male (%) 44 (79%)
ART (%) 15 (27%)
HCV Co-infection (%) 6 (11%)
Drugs (%) 9 (16%)
CD4 (median) cel/µl 31cel/µl (IRQ=61)
HIV Viral load (mean) copies/ml 284050 copies/ml (IRQ=631625)
Previous opportunistic infection (%) 15 (27%)
ICU admission (%) 19 (34%)
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 Mechanical ventilation (%) 12 (21%)
Overall mortality (%) 10 (18%)
Fever (%) 33 (59%)
Associated comorbidities (%) 20 (36%)
Mortality from respiratory infection (%) 5 (9%)
CMV viral load in blood 11,15 copies/ml (IRQ=85.24)
CMV viral load in BLA 66 copies/ml (IRQ=1466.9)
Sexual trasmission (%) 48 (88%)
Respiratory isolations (%) 34 (61%)
Pneumocystis jirovencii 21 (68%)
Haemophilus influenzae influenzae 2 (6%)
Klebsiella pneumoniae 1 (3%)
Pseudomona aerouginosa 1 (3%)
Streptococcus pneumoniae 1 (3%)
CMV 5 (16%)
Mycobacterium tuberculosis 3 (9%)
ART, Antiretroviral therapy; BAL, bronchoalveolar lávage; ICU, Intensive care unit; HCV, Hepatitis C virus.
Table 2. Active infection by cytomegalovirus (AICMV) clinical manifestations.
Respiratory (n) 34 (61%)
Digestive (n) 8 (14%)
Neurological (n) 8 (14%)
Dermatological (n) 2 (3%)
Hematological (n) 3 (5%)
Ophthalmic (n) 0 (0%)
Cardiological (n) 1 (2%)
Table 3. Predictors of mortality.
Qualitative Variables and Mortality
VARIABLE Association CHI² P
Gender No 0.902 0.761
ART No 2.597 0.107
HIV transmission No 1.141 0.285
HCV coinfection No 0 1
Comorbidities No 0 1
Smoker No 0 1
Drugs No 0.221 0.638
Opportunistic infections No 1.936 0.164
ICU admission YES 17.7 <0.001
Mechanical ventilation YES 28.3 <0.001
Fever NO 0.071 0.965
Clinical manifestations NO 0.078 0.781
Quantitative Variables and Mortality
MORTALITY N Median IQR p
CD4 lymphocytes YES 10 82.2 54 0.672
No 46 114.6 60
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CD8 lymphocytes YES 10 540.4 633 0.482
No 46 710.7 534
Viral load VIH YES 10 1889327.1 894828.0 0.549
No 46 850621.2 610775
%CD4 YES 10 11.3 9.0 0.278
No 46 8.1 6.2
%CD8 YES 10 64.5 15.3 0.702
No 46 62.4 24.3
Leukocytes YES 10 6890.0 2950 0.854
No 46 7236.5 490
Hemoglobin YES 10 11.4 3.15 0.753
No 46 11.6 2.6
Platelets YES 10 225800.0 162500 0.536
No 46 330413.0 196750
GOT YES 10 44.0 60 0.738
No 45 49.0 36
Direct bilirubin YES 9 0.5 0.6 0.080
No 45 0.2 0.1
GPT YES 10 26.0 15 0.269
No 46 46.5 29
GGT YES 10 114.5 110 0.995
No 39 114.0 42
LDH YES 10 856.5 546 0.622
No 42 778.8 643
ART, Antiretroviral therapy; GGT, gamma glutamyl transpeptidase; GPT, glutamic-pyruvic transaminase; IQR, interquartile range; 
LDH, lactate dehydrogenase; OT, Glutamic oxaloacetic transaminase; ICU I, Intensive care unit; HCV, hepatitis C virus.
DISCUSSION
Lower respiratory tract infection is the 
most common infection in HIV-infected 
patients, and sometimes it is the first clini-
cal manifestation of infection. (10) Our 
study confirms this and adds that this is 
also the case in AICMV. Pneumonia was 
the most common presentation of res-
piratory infection (31 cases) and the most 
common cause was P. jirovecii, unlike 
what was described in the literature pre-
viously, where the main bacterial etiology 
remains mainly at the expense of S. pneu-
monia. (11) In our series, there were only 
four bacterial isolates and among them S. 
pneumoniae was the only one. This is due 
to the degree of severe immunosuppres-
sion in our patients who had not started 
ART (because being infected with HIV 
was unknown before admission to ED), or 
because they were in the first 6 months of 
treatment, where ART had not yet reached 
its maximum effectiveness. Pulmonary in-
volvement with CMV infection in the form 
of pneumonitis has a similar presentation 
to the one with P. jirovecii infection, which 
can lead to confusion and errors in treat-
ment. (12) The patients with TB did not 
show any mortality in our series. Howev-
er, this information should be taken with 
caution because our sample size is very 
small. Recent World Health Organization 
(WHO) studies also show that TB is re-
sponsible for up to one quarter of deaths of 
HIV-infected patients, especially when the 
infection is advanced. (13,14)
The highest percentage of respiratory 
manifestations in HIV-infected patients 
with AICMV shows a change in clinical 
presentation. Until now, according to the 
data reported in the scientific literature, 
ocular and gastrointestinal manifestations 
are the ones seen most frequently. (15) 
In our series, despite the high number of 
patients with immunosuppression, it was 
surprising that no patient had retinitis, but 
this is consistent with previous studies that 
have shown a decrease in retinitis, caused 
by CMV, in the cART era. (16)
The overall mortality in this study was 
18%, and the leading cause of death was 
respiratory infection (9%). Mortality was 
higher in patients admitted to the ICU, as 
in previous studies. (17) Our work con-
trasts with the findings of Lichtner et al. 
(18) where cardiovascular and neurologi-
cal events, attributed to immune dysfunc-
tion due to HIV / CMV coinfection, were 
the leading causes of death. CMV is an 
immunomodulatory virus which favors 
the appearance of opportunistic diseases, 
and the vast majority of HIV patients have 
a coinfection at some point in their life, 
leading to increased activation of the im-
mune system, even if they are on cART, 
(19) with a consequent increase in mor-
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bidity and mortality. Early identification 
of CMV infection can prevent the onset 
of opportunistic infections. Based on the 
above, we believe that detection should be 
early, requesting, if there is any suspicion, 
diagnostic tests in the same HED and BAL 
since, as we have seen, higher viral load of 
CMV in BAL leads to increased mortality.
LIMITATIONS
Among the limitations of our study we 
emphasize that this is a single-center, ret-
rospective study based on laboratory con-
firmation of CMV infection with a small 
number of cases.
CONCLUSION
In HIV patients, respiratory infection is 
the most common manifestation of AI-
CMV, and is caused by opportunistic mi-
croorganisms, resulting in a 9% mortality.
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